Christine Eberhardt
- ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthmaBy Sally Wenzel, David Chantry, Christine Eberhardt, Robert Hopkins, Michael Saunders, Lisa Anderson, Roger Aitchinson, Stacie Bell, Kenji Izuhara, Junya Ono and Laurence BurgessSally Wenzel1School of Medicine, University of Pittsburgh Asthma Institute, Pittsburgh, PA,David Chantry2Drug Discovery and Development, Array BioPharma, Boulder, CO,Christine Eberhardt2Drug Discovery and Development, Array BioPharma, Boulder, CO,Robert Hopkins2Drug Discovery and Development, Array BioPharma, Boulder, CO,Michael Saunders2Drug Discovery and Development, Array BioPharma, Boulder, CO,Lisa Anderson2Drug Discovery and Development, Array BioPharma, Boulder, CO,Roger Aitchinson2Drug Discovery and Development, Array BioPharma, Boulder, CO,Stacie Bell2Drug Discovery and Development, Array BioPharma, Boulder, CO,Kenji Izuhara3Department of BioMedical Sciences, Saga Medical School, Saga, JapanJunya Ono4Research and Development, Shino-Test Corporation, Tokyo, JapanLaurence Burgess2Drug Discovery and Development, Array BioPharma, Boulder, CO,
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.